EA201891731A1 - OPTIMIZED FACTOR VIII GENES - Google Patents
OPTIMIZED FACTOR VIII GENESInfo
- Publication number
- EA201891731A1 EA201891731A1 EA201891731A EA201891731A EA201891731A1 EA 201891731 A1 EA201891731 A1 EA 201891731A1 EA 201891731 A EA201891731 A EA 201891731A EA 201891731 A EA201891731 A EA 201891731A EA 201891731 A1 EA201891731 A1 EA 201891731A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- factor viii
- codon
- optimized
- optimized sequences
- optimized factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Согласно настоящему изобретению предложены кодон-оптимизированные последовательности фактора VIII, векторы и клетки-хозяева, содержащие кодон-оптимизированные последовательности фактора VIII, полипептиды, кодируемые кодон-оптимизированными последовательностями фактора VIII, и способы получения таких полипептидов. Согласно настоящему изобретению также предложены способы лечения расстройств системы свертывания крови, таких как гемофилия, включающие введение субъекту кодон-оптимизированной последовательности нуклеиновой кислоты фактора VIII или кодируемого указанной последовательностью полипептида.According to the present invention, codon-optimized sequences of factor VIII, vectors and host cells containing codon-optimized sequences of factor VIII, polypeptides encoded by codon-optimized sequences of factor VIII, and methods for producing such polypeptides are proposed. The present invention also provides methods for treating blood coagulation disorders, such as hemophilia, comprising administering to the subject a codon-optimized nucleic acid sequence of factor VIII or encoded by the indicated polypeptide sequence.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662409739P | 2016-10-18 | 2016-10-18 | |
PCT/US2017/015879 WO2017136358A1 (en) | 2016-02-01 | 2017-01-31 | Optimized factor viii genes |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201891731A1 true EA201891731A1 (en) | 2019-04-30 |
Family
ID=66436966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201891731A EA201891731A1 (en) | 2016-10-18 | 2017-01-31 | OPTIMIZED FACTOR VIII GENES |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA201891731A1 (en) |
-
2017
- 2017-01-31 EA EA201891731A patent/EA201891731A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501628A1 (en) | Optimized factor viii genes | |
PH12019500694A1 (en) | Factor viii compositions and methods of making and using the same | |
EP4223772A3 (en) | Optimized factor viii gene | |
EA201890640A1 (en) | RECOMBINANT VECTORS CONTAINING PEPTIDE 2A | |
EA201891092A1 (en) | METHODS AND COMPOSITIONS FOR EDITING GENES IN HEMOPOETIC STEM CELLS | |
PH12018502361A1 (en) | Gdf15 fusion proteins and uses thereof | |
SA518400424B1 (en) | Antibody molecules for cancer treatment | |
MX2019006045A (en) | Psma targeting trispecific proteins and methods of use. | |
EA202091710A1 (en) | ANTIBODIES AGAINST CD73 AND METHODS OF THEIR USE | |
EA201792573A1 (en) | TRISPECIFIC RELATED PROTEINS AND METHODS OF THEIR APPLICATION | |
EA201990715A1 (en) | STABILIZING TRIMER MUTATIONS OF THE PROTEIN OF THE SHELL OF HIV | |
WO2017011773A3 (en) | Codon-optimized nucleic acids encoding antibodies | |
MX2015014464A (en) | Gene-therapy vectors for treating cardiomyopathy. | |
PH12019500122A1 (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
EA201691576A1 (en) | SLIT PROTEINS CONTAINING INTERLEUKIN-2 AND THEIR APPLICATIONS | |
AU2015286820A8 (en) | Stabilization of poly(A) sequence encoding DNA sequences | |
MX2019015502A (en) | Modified l-asparaginase. | |
JP2016520320A5 (en) | ||
MX2017014716A (en) | Anti-cancer fusion polypeptide. | |
NZ752941A (en) | Frataxin expression constructs | |
EA201890351A1 (en) | RECOMBINANT ORF-VIRAL VECTOR | |
EA201891731A1 (en) | OPTIMIZED FACTOR VIII GENES | |
EA201790362A1 (en) | LOVED ENZYME AND ITS APPLICATIONS | |
NZ774631A (en) | Composition for preventing or treating benign tumor | |
PH12019502442A1 (en) | Variants of human bmp7 protein |